Millennium Management’s Apellis Pharmaceuticals APLS Stock Holding History

Millennium Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$346K	Buy	+8,600	New	+$185K	﹤0.01%	4943
2024 Q4	–	Sell	-7,800	Closed	-$225K	–	5926
2024 Q3	$225K	Sell	7,800 -4,300	-36%	-$159K	﹤0.01%	5374
2024 Q2	$464K	Sell	12,100 -57,400	-83%	-$2.6M	﹤0.01%	4641
2024 Q1	$4.09M	Buy	69,500 +46,600	+203%	+$2.97M	﹤0.01%	3081
2023 Q4	$1.37M	Sell	22,900 -80,500	-78%	-$4.08M	﹤0.01%	3910
2023 Q3	$3.93M	Buy	103,400 +79,200	+327%	+$3.48M	﹤0.01%	2933
2023 Q2	$2.2M	Buy	+24,200	New	+$2.09M	﹤0.01%	3394
2022 Q4	–	Sell	-80,000	Closed	-$5.46M	–	6551
2022 Q3	$5.46M	Buy	+80,000	New	+$4.73M	﹤0.01%	2808
2021 Q4	–	Sell	-16,000	Closed	-$527K	–	6739
2021 Q3	$527K	Buy	+16,000	New	+$899K	﹤0.01%	5298
2020 Q1	–	Sell	-108,800	Closed	-$3.33M	–	3811
2019 Q4	$3.33M	Buy	+108,800	New	+$3.01M	﹤0.01%	2244

Other funds holding APLS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management's APLS Position: Q1 2026 in Review

Millennium Management increased its Apellis Pharmaceuticals (APLS) stake by 138% in Q1 2026, buying an estimated $28.2M and bringing the position to 2,256,802 shares worth $90.8M. The position accounts for 0.04% of the portfolio, ranked #491.

Millennium Management first reported a position in APLS in Q2 2018 and has held it in 30 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

Millennium Management held 2,256,802 shares of Apellis Pharmaceuticals worth $90.8M as of Q1 2026.
Millennium Management bought 1,310,343 Apellis Pharmaceuticals shares in Q1 2026, an estimated $28.2M.
Apellis Pharmaceuticals made up 0.04% of Millennium Management's portfolio in Q1 2026, its #491 holding.
Millennium Management first reported a position in Apellis Pharmaceuticals in Q2 2018 and has held it in 30 quarters since.
321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.